AR035676A1 - Formulacion farmaceutica que contiene pirazolo[4,3-d]pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina - Google Patents
Formulacion farmaceutica que contiene pirazolo[4,3-d]pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandinaInfo
- Publication number
- AR035676A1 AR035676A1 ARP010105888A ARP010105888A AR035676A1 AR 035676 A1 AR035676 A1 AR 035676A1 AR P010105888 A ARP010105888 A AR P010105888A AR P010105888 A ARP010105888 A AR P010105888A AR 035676 A1 AR035676 A1 AR 035676A1
- Authority
- AR
- Argentina
- Prior art keywords
- effective amount
- pyrazolo
- prostaglandin
- acid
- pharmaceutical formulation
- Prior art date
Links
- 229940127291 Calcium channel antagonist Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- LIFZVJKHTQXNLW-UHFFFAOYSA-N 2-[[7-[(3-chloro-4-methoxyphenyl)methylamino]-1-methyl-3-propylpyrazolo[4,3-d]pyrimidin-5-yl]methoxy]acetic acid Chemical compound N1=C(COCC(O)=O)N=C2C(CCC)=NN(C)C2=C1NCC1=CC=C(OC)C(Cl)=C1 LIFZVJKHTQXNLW-UHFFFAOYSA-N 0.000 abstract 2
- -1 COOA Chemical group 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 230000002785 anti-thrombosis Effects 0.000 abstract 2
- 239000003146 anticoagulant agent Substances 0.000 abstract 2
- 239000000480 calcium channel blocker Substances 0.000 abstract 2
- 150000002169 ethanolamines Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 206010039163 Right ventricular failure Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000023819 chronic asthma Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- DSKLYHDHQJANOE-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidine Chemical group C1=NC=N[C]2C=NN=C21 DSKLYHDHQJANOE-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000012201 sexual and gender identity disease Diseases 0.000 abstract 1
- 208000015891 sexual disease Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formulación farmacéutica que contiene al menos una pirazolo [4,3-d]pirimidina de fórmula (1) donde R1, R2 son cada uno, independientemente entre sí, H, A, OH, OA, o Hal, R1 y R2 juntos, son tambien alquileno C3-5, -O-CH2-CH2, -CH2-O-CH2, -O-CH2-O- o -O-CH2-CH2-O-, R3, R4 son cada uno, independientemente entre sí H, o A, X es R5, R6 o R7 monosustituido con R8, R5 es alquileno de cadena recta o ramificada C1-10 donde uno o dos grupos CH2 pueden estar reemplazados por grupos CH=CH, O, S o SO, R6 es cicloalquilo o cicloalquilalquileno C5-12, R7 es fenilo o fenilmetilo, R8 es COOH, COOA, CONH2, CONHA, CON(A)2, o CN, A es alquilo C1-6 y Hal es F, Cl, Br o I y/o sus sales y/o solvatos aceptables para uso farmacéutico, y a) por lo menos un antitrombótico o b) por lo menos un antagonista del calcio o c)por lo menos una prostaglandina o un derivado de prostaglandina. Los compuestos de fórmula (1) presentan una inhibición específica de la fosfodiesterasa GMPc (PDE V) . también se describe: 1) un conjunto (Kit) que en envases separados comprende (a) una cantidad efectiva de ácido [7-(3-cloro-4-metoxi-bencilamino)-1-metil-3-propil-1H-pirazolo[4,3-d]-pirimidin-5-ilmetoxi]-acético y (b) una cantidad efectiva de un antitrombótico; 2) un conjunto (Kit) que en envases separados comprende a) una cantidad efectiva de sal de etanolamina del ácido [7-(3-cloro-4-metoxi-bencilamino)-1-metil-3-propil-1H-pirazolo[4,3-d]-pirimidin-5-ilmetoxi]-acético, y b) una cantidad efectiva de un antagonista de calcio; 3)un conjunto (kit) que en envases separados comprende a) una cantidad efectiva de sal de etanolamina del ácido [7-(3-cloro-4-metoxi-bencilamino)-1-metil-3-propil-1H-pirazolo[4,3-d]-pirimidin-5-ilmetoxi]-acético, y b) una cantidad efectiva de una prostaglandina o un derivado de prostaglandina. La formulación farmacéutica anteriormente mencionada se usa para preparar un medicamento para el tratamiento de angina, hipertensión, hipertensión pulmonar, deficiencia cardíaca congestiva (CHF), enfermedad pulmonar obstructiva crónica (COPD), Cor pulmonar, insuficiencia cardíaca derecha, arterioesclerosis, reducción de la circulación en los vasos cardíacos, enfermedades vasculares periféricas, apoplejía, bronquitis, asma alérgico, asma crónico, rinitis alérgica, glaucoma, síndrome de colon irritable, tumores, insuficiencia renal, cirrosis, hepática y para el tratamiento de desórdenes sexuales femeninos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10063224A DE10063224A1 (de) | 2000-12-19 | 2000-12-19 | Pharmazeutische Formulierung enthaltend Pyrazolo(4,3-d)pyrimidine und Antithrombotica |
| DE2000163882 DE10063882A1 (de) | 2000-12-21 | 2000-12-21 | Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Calcium-Antagonisten |
| DE2000164993 DE10064993A1 (de) | 2000-12-23 | 2000-12-23 | Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Prostaglandine oder Prostaglandinderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035676A1 true AR035676A1 (es) | 2004-06-23 |
Family
ID=27214208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105888A AR035676A1 (es) | 2000-12-19 | 2001-12-19 | Formulacion farmaceutica que contiene pirazolo[4,3-d]pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040063730A1 (es) |
| EP (1) | EP1343506A1 (es) |
| JP (1) | JP2004516270A (es) |
| KR (1) | KR20030059349A (es) |
| CN (1) | CN1481244A (es) |
| AR (1) | AR035676A1 (es) |
| AU (1) | AU2002229573A1 (es) |
| BR (1) | BR0115995A (es) |
| CA (1) | CA2431077A1 (es) |
| CZ (1) | CZ20031776A3 (es) |
| HU (1) | HUP0303315A2 (es) |
| MX (1) | MXPA03005393A (es) |
| NO (1) | NO20032773L (es) |
| PL (1) | PL362513A1 (es) |
| SK (1) | SK8192003A3 (es) |
| WO (1) | WO2002049651A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035531A1 (es) * | 2001-01-22 | 2004-06-02 | Novartis Ag | Composicion para el control de plagas endoparasiticas en ganados y animales domesticos, un metodo para su control y el uso de dicha composicion para la preparacion de medicamentos |
| DE60237425D1 (de) * | 2002-03-28 | 2010-10-07 | Univerzita Palackeho V Olomouc | PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung |
| DE10229778A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Neue Verwendung von Imidazotriazinonen |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| KR100468352B1 (ko) * | 2002-09-24 | 2005-01-27 | 한국과학기술연구원 | 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물 |
| JP4015176B2 (ja) | 2003-04-29 | 2007-11-28 | ファイザー・インク | 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類 |
| DK1628663T3 (da) * | 2003-05-15 | 2010-03-08 | Roskamp Res Llc | Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose |
| US7572799B2 (en) * | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| GB0327323D0 (en) * | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
| EP1742950B1 (en) * | 2004-04-07 | 2008-12-17 | Pfizer Limited | Pyrazolo[4,3-d] pyrimidines |
| WO2008121386A2 (en) * | 2007-03-30 | 2008-10-09 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
| ES2449594T3 (es) * | 2007-10-05 | 2014-03-20 | Alzheimer's Institute Of America, Inc. | Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina |
| US20100093810A1 (en) * | 2007-10-05 | 2010-04-15 | Alzheimer's Institute Of America, Inc. | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis |
| KR101678699B1 (ko) * | 2008-08-13 | 2016-11-23 | 액테리온 파마슈티칼 리미티드 | 마시텐탄을 포함하는 치료 조성물 |
| CN107106541A (zh) * | 2015-01-28 | 2017-08-29 | 瑞采生技有限公司 | 用于增强PPARγ表现及核转位之化合物及其医疗用途 |
| MA46191A (fr) | 2016-09-09 | 2021-04-21 | Incyte Corp | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| TWI778050B (zh) | 2017-04-21 | 2022-09-21 | 美商醫肯納腫瘤學公司 | 吲哚ahr抑制劑及其用途 |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| LT3755703T (lt) | 2018-02-20 | 2022-10-10 | Incyte Corporation | N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| ES2973117T3 (es) | 2018-09-25 | 2024-06-18 | Incyte Corp | Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR |
| CR20220097A (es) | 2019-08-06 | 2022-06-01 | Incyte Corp | Formas sólidas de un inhibidor de hpk1 |
| WO2021108528A1 (en) | 2019-11-26 | 2021-06-03 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2353285A1 (fr) * | 1975-09-17 | 1977-12-30 | Doms Laboratoires | Medicament vasodilatateur coronarien perfectionne |
| JPS5459266A (en) * | 1977-10-14 | 1979-05-12 | Ono Pharmaceut Co Ltd | Prostaglandin i2 analogs and their preparation |
| FR2568774B2 (fr) * | 1984-05-30 | 1989-05-19 | Choay Sa | Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique |
| FR2672601B1 (fr) * | 1991-02-08 | 1994-10-14 | Synthelabo | Derives de benzo-1,5-thiazepine, leur preparation et leur application en therapeutique. |
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| DE19709877A1 (de) * | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| JP2003525845A (ja) * | 1997-10-28 | 2003-09-02 | ヴィヴァス・インコーポレイテッド | 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与 |
| DE19942474A1 (de) * | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
| DE10058662A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Pyrazolo[4,3-d]pyrimidinen |
| DE10103647A1 (de) * | 2001-01-27 | 2002-08-01 | Merck Patent Gmbh | Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates |
-
2001
- 2001-11-28 CA CA002431077A patent/CA2431077A1/en not_active Abandoned
- 2001-11-28 AU AU2002229573A patent/AU2002229573A1/en not_active Abandoned
- 2001-11-28 WO PCT/EP2001/013916 patent/WO2002049651A1/de not_active Ceased
- 2001-11-28 JP JP2002550991A patent/JP2004516270A/ja active Pending
- 2001-11-28 CZ CZ20031776A patent/CZ20031776A3/cs unknown
- 2001-11-28 MX MXPA03005393A patent/MXPA03005393A/es not_active Application Discontinuation
- 2001-11-28 KR KR10-2003-7008078A patent/KR20030059349A/ko not_active Withdrawn
- 2001-11-28 BR BR0115995-0A patent/BR0115995A/pt not_active Application Discontinuation
- 2001-11-28 EP EP01990452A patent/EP1343506A1/de not_active Withdrawn
- 2001-11-28 US US10/451,105 patent/US20040063730A1/en not_active Abandoned
- 2001-11-28 CN CNA018209165A patent/CN1481244A/zh active Pending
- 2001-11-28 PL PL01362513A patent/PL362513A1/xx unknown
- 2001-11-28 SK SK819-2003A patent/SK8192003A3/sk unknown
- 2001-11-28 HU HU0303315A patent/HUP0303315A2/hu unknown
- 2001-12-19 AR ARP010105888A patent/AR035676A1/es unknown
-
2003
- 2003-06-18 NO NO20032773A patent/NO20032773L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1481244A (zh) | 2004-03-10 |
| AU2002229573A1 (en) | 2002-07-01 |
| NO20032773D0 (no) | 2003-06-18 |
| WO2002049651A1 (de) | 2002-06-27 |
| NO20032773L (no) | 2003-06-18 |
| HUP0303315A2 (hu) | 2004-01-28 |
| SK8192003A3 (en) | 2003-10-07 |
| CZ20031776A3 (cs) | 2003-09-17 |
| KR20030059349A (ko) | 2003-07-07 |
| EP1343506A1 (de) | 2003-09-17 |
| PL362513A1 (en) | 2004-11-02 |
| US20040063730A1 (en) | 2004-04-01 |
| MXPA03005393A (es) | 2003-09-25 |
| BR0115995A (pt) | 2004-01-13 |
| JP2004516270A (ja) | 2004-06-03 |
| CA2431077A1 (en) | 2002-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035676A1 (es) | Formulacion farmaceutica que contiene pirazolo[4,3-d]pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina | |
| US9951075B2 (en) | Pteridines useful as HCV inhibitors and methods for the preparation thereof | |
| ES2341572T3 (es) | Pirido(2,3-d)-pirimidinas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas. | |
| ES2617619T3 (es) | Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR | |
| RU2003117478A (ru) | Применение тиенопиримидинов | |
| AR037680A1 (es) | Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d | |
| RU2006134003A (ru) | Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| CA2192470A1 (en) | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf | |
| PE20051061A1 (es) | 5,7-DIAMINOPIRAZOLO[4,3-d] PIRIMIDINAS | |
| JP2017523219A5 (es) | ||
| CZ153795A3 (en) | Novel antagonists of corticotropin releasing factor | |
| BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
| RU2004114239A (ru) | Производные пиримидина | |
| EE03003B1 (et) | Angiotensiin II retseptorite antagonistidena toimivad triasolopürimidiinide derivaadid, ravimvormid, nende valmistamise meetodid | |
| AR035373A1 (es) | Uso de pirazolo(4,3-d]pirimidinas | |
| HRP20100681T1 (hr) | Derivati hinaholina korisni za tretman periferne arterijske bolesti i kao inhibitori fosfodiesteraze | |
| AR035741A1 (es) | Formulacion farmaceutica que comprende pirazolo (4,3-d)pirimidinas y nitratos o tienopirimidinas y nitratos, una preparacion farmaceutica a base de estos componentes, y un conjunto de elementos (kit) que contiene estos componentes en envases independientes. | |
| AR032009A1 (es) | Formulacion farmaceutica que contiene tienopirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina | |
| AR035675A1 (es) | Formulacion farmaceutica que contiene tienopirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandinas, el uso de las mismas para preparar un medicamento , y un conjunto (kit) que contiene los componentes de la formulacion en envases separados | |
| ECSP067111A (es) | Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica | |
| CA1227428A (en) | Anti-ulcer agents | |
| MX2021005892A (es) | Novedosos activadores de guanilato ciclasa soluble e inhibidores de fosfodiesterasa con modo de accion dual y usos de estos. | |
| JP2004506619A (ja) | 性的機能障害用医薬 | |
| JP2007509099A5 (es) | ||
| RU2447074C2 (ru) | Птеридины, полезные в качестве ингибиторов hcv, и способы получения птеридинов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |